NASDAQ$IONS
Ionis Pharmaceuticals · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Ionis reported financial results for Q2 2020, highlighting commercial and R&D revenue growth and a strong cash position.
Ionis Pharmaceuticals reported a net loss of $32 million on a GAAP basis but achieved net income of $8 million on a non-GAAP basis. The company saw growth in commercial and R&D revenues and maintained a strong cash position of over $2.3 billion.
- Achieved net income on a non-GAAP basis.
- Commercial revenue from SPINRAZA royalties increased to $72 million.
- Product sales from TEGSEDI and WAYLIVRA increased to $16 million.
- R&D revenue increased to more than $55 million.
Headline financials
Revenue & EPS history
Ionis · Revenue · Quarterly
$146M
Revenue by segment
Ionis · $151M total across 2 segments · Q2 2023
- Collaborative Agreement Rev$90M+130.8%59.6%
- SPINRAZA Royalties$61M+1.7%40.4%
Forward guidance
Ionis is maintaining its 2020 financial guidance and expects revenue and earnings growth in the second half of this year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+1.2%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+30.2%
Q3 2016
Best reaction
-13.5%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +5.1% | +6.6% | |
| Q4 2025 | -5.3% | -4.1% | -15.6% | |
| Q3 2025 | -2.3% | +0.1% | +12.5% | |
| Q1 2025 | +3.0% | +12.9% | +12.4% | |
| Q4 2024 | -0.4% | -0.2% | +3.0% | |
| Q3 2024 | -0.9% | +0.2% | -1.8% | |
| Q2 2024 | -0.7% | -4.9% | -3.6% | |
| Q1 2024 | -5.0% | -7.6% | -5.7% | |
| Q4 2023 | -0.8% | +3.9% | -3.7% | |
| Q3 2023 | +4.3% | +5.4% | +14.1% | |
| Q2 2023 | +0.7% | +0.8% | +4.2% | |
| Q1 2023 | +1.3% | -1.0% | +17.5% | |
| Q4 2022 | -4.0% | -5.3% | -11.2% | |
| Q3 2022 | +7.6% | +4.2% | -11.2% | |
| Q2 2022 | +0.9% | -3.5% | -3.2% | |
| Q1 2022 | -1.2% | -17.6% | -6.1% | |
| Q4 2021 | +3.4% | +10.9% | +19.3% | |
| Q3 2021 | +5.0% | +5.8% | -20.0% | |
| Q2 2021 | +4.2% | +2.0% | +4.5% | |
| Q1 2021 | -11.1% | -13.7% | -17.7% | |
| Q4 2020 | -4.7% | -3.6% | -23.4% | |
| Q3 2020 | +3.7% | +6.6% | +9.0% | |
| Q2 2020 | -4.6% | -8.7% | -6.1% | |
| Q1 2020 | -7.7% | -2.7% | -0.3% | |
| Q4 2019 | -3.6% | -5.4% | -10.7% | |
| Q3 2019 | +1.8% | +4.2% | +18.8% | |
| Q2 2019 | +6.6% | +6.2% | -3.6% | |
| Q1 2019 | +0.9% | -2.8% | -7.2% | |
| Q4 2018 | +15.2% | +14.4% | +31.7% | |
| Q3 2018 | +5.4% | -0.0% | +8.8% | |
| Q2 2018 | +4.4% | +11.6% | +1.9% | |
| Q1 2018 | +7.4% | +3.7% | +12.9% | |
| Q4 2017 | +2.8% | -4.7% | -14.2% | |
| Q3 2017 | +0.9% | +3.0% | -0.6% | |
| Q2 2017 | -8.6% | -11.0% | +7.4% | |
| Q1 2017 | -2.6% | +3.9% | +10.3% | |
| Q4 2016 | +5.4% | +16.6% | -13.8% | |
| Q3 2016 | +30.2% | +51.0% | +44.9% | |
| Q2 2016 | +0.1% | -2.5% | -14.1% | |
| Q1 2016 | -8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | +14.8% | — | — | |
| Q2 2015 | +1.0% | — | — | |
| Q1 2015 | +1.2% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +4.4% | — | — | |
| Q2 2014 | +6.3% | — | — | |
| Q1 2014 | -6.5% | — | — | |
| Q4 2013 | -9.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | -12.4% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -7.0% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | +7.6% | — | — | |
| Q4 2011 | +2.8% | — | — | |
| Q3 2011 | -13.5% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -2.7% | — | — | |
| Q1 2011 | +2.8% | — | — | |
| Q4 2008 | -1.6% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q4 2009 | -3.8% | — | — | |
| Q2 2010 | -3.8% | — | — | |
| Q2 2009 | -3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro